

## TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 021395 AND 022495—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
K N Energy, Inc., Burlington Resources, Inc., Meridian Oil Hydrocarbons Inc., Meridian Oil Storage	95-0899	02/14/95
Harnischfeger Industries, Inc., Rochling Industrie Verwaltung GmbH, Jagenberg Papiertechnik GmbH and Jagenberg Inc	95-0458	02/15/95
The Hillhaven Corporation, The Hillhaven Corporation, The Hillhaven Corporation	95-0987	02/16/95
Shurgard Storage Centers, Inc., Shurgard Incorporated, Shurgard Incorporated	95-0933	02/17/95
American International Group, Inc., Robert H. Ledbetter, Cobb Retail Associates	95-0938	02/17/95
American International Group, Inc., Stephen H. Whisenant, Cobb Retail Associates	95-0940	02/17/95
Harvest States Cooperative, H.J. Heinz Company, Portion Pac Inc	95-0941	02/17/95
Mitsui & Co., Ltd., H.J. Heinz Company, Portion Pac Inc	95-0950	02/17/95
Apache Corporation, DEKALB Energy Company, DEKALB Energy Company	95-0964	02/17/95
The Parsons Corporation, Sidney Epstein, A. Epstein and Sons International, Inc	95-0991	02/17/95
WHX Corporation, Ohio Coatings Company (Joint Venture), Ohio Coatings Company (Joint Venture)	95-0994	02/17/95
Dong Yang Tinplate Ind. Co., Ltd., Ohio Coating Company (Joint Venture), Ohio Coating Company (Joint Venture)	95-0995	02/17/95
Tostem Corporation, Alumax Inc., Washington Newco and Maryland Newco	95-1010	02/17/95
Mitsui & Co., Ltd., Alumax Inc., Washington Newco and Maryland Newco	95-1011	02/17/95
CPF Acquisition Co., Inc., William H. Kopman, Universal Premium Acceptance Corporation	95-0917	02/21/95
The Superior Gen. & Councilors/Franciscan Sisters Mercy, Oklahoma Orthopedic and Arthritis Foundation, Inc., Oklahoma Orthopedic and Arthritis Foundation, Inc	95-0919	02/21/95
Catholic Healthcare West, Daughters of Charity National Health System, Inc., Daughters of Charity National Health System-West, Inc	95-0936	02/21/95
K-III Communications Corporation, Jonathan Adler, The Adler Group, Inc, and WJA, Inc	95-0973	02/21/95
K-III Communications Corporation, Warren Adler, The Adler Group, Inc., and WJA, Inc	95-0974	02/21/95
The Travelers Inc., Warburg Pincus Investors, L.P., HealthSpring, Inc	95-0975	02/21/95
Metropolitan Life Insurance Company, Warburg Pincus Investors, L.P., HealthSpring, Inc	95-0976	02/21/95
Warburg, Pincus Investors, L.P., The Travelers, Inc., The MetraHealth Companies, Inc	95-0977	02/21/95
The Jaguar fund N.V., Peter Munk, Clark USA, Inc	95-1005	02/21/95
Tiger (a limited partnership), Peter Munk, Clark USA, Inc	95-1009	02/21/95
Credence Systems Corporation, EPRO Corporation, EPRO Corporation	95-1017	02/21/95
Victor Forss, E.I. DuPont de Nemours and Company, Conoco	95-1018	02/21/95
Svenska Cellulosa Aktiebolaget SCA, Scott Paper Company, Scott Health Care (SHC) Health Care Company (HCC)	95-1021	02/21/95
A. Schulman Inc., J.M. Huber Corporation, J.M. Huber Corporation	95-1027	02/21/95
Fairview Hospital and Healthcare Services, Ebenezer Society, Ebenezer Society	95-1037	02/21/95
Renal Treatment Centers, Inc., Robert I. Falk, Healthcare Corporation	95-1044	02/21/95
Robert I. Falk, Renal Treatment Centers, Inc., Renal Treatment Centers, Inc	95-1045	02/21/95
Consolidated Electrical Distributors, Inc., Hughes Supply, Inc., Hughes Supply, Inc	95-0968	02/22/95
D & K Wholesale Drug, Inc., Krelitz Industries, Inc., Krelitz Industries, Inc	95-1000	02/22/95
Thayer Hotel Investors II L.P., Great Western Financial Corporation, Twinbrook Business Center Incorporated	95-1001	02/22/95
Ricoh Company, Ltd., Savin Corporation, Savin Corporation	95-1029	02/22/95
Ronald W. Burkle, Dodi Family L.L.C., Dodi, Inc	95-1038	02/22/95
National Medical Enterprises, Inc., South Dade Health Care Ventures, L.L.C., South Dade Health Care Ventures, L.L.C	95-0951	02/23/95
South Miami Health System, Inc., South Dade Health Care Ventures, L.L.C., South Dade Health Care Ventures, L.L.C	95-0952	02/23/95
AT&T Corp., LiteSpec Limited Liability Company, LiteSpec Limited Liability Company	95-0966	02/23/95
Ira Leon Rennert, UNR Asbestos-Disease Claims Trust, UNR Industries, Inc	95-1028	02/23/95
California Microwave, Inc., Microwave Networks Incorporated, Microwave Networks Incorporated	95-1007	02/24/95
Arthur W. Epley III, California Microwave, Inc., California Microwave, Inc	95-1008	02/24/95
Holland Chemical International, B.V., Philip M. Segal, Jr., Worth Chemical Corporation	95-1025	02/24/95
American Home Products Corporation, Affymax N.V., Affymax N.V	95-1049	02/24/95

**FOR FURTHER INFORMATION CONTACT:**

Sandra M. Peay or Renee A. Horton,  
Contact Representatives, Federal Trade  
Commission, Premerger Notification  
Office, Bureau of Competition, Room  
303, Washington, D.C. 20580, (202) 326-  
3100.

By Direction of the Commission.

**Donald S. Clark,**

Secretary.

[FR Doc. 95-5788 Filed 3-8-95; 8:45 am]

BILLING CODE 6750-01-M

[Dkt. C-3557]

**American Home Products Corporation;  
Prohibited Trade Practices, and  
Affirmative Corrective Actions**

**AGENCY:** Federal Trade Commission.

**ACTION:** Consent order.

**SUMMARY:** In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair method of competition—in connection with American Home Products Corporation's acquisition of American Cyanamid Company—this consent order requires, among other things, the New

Jersey-based corporation to divest its tetanus and diphtheria vaccine business to a Commission-approved buyer; to license Cyanamid's rotavirus vaccine research to a Commission-approved licensee; and to change a previously established licensing agreement to ensure that it does not obtain certain competitively sensitive information. The consent order also prohibits, for ten years, the respondent from acquiring any interest in any entity engaged in the clinical development, manufacture, or sale of tetanus, diphtheria, or rotavirus vaccines in the United States without prior Commission approval.

**DATES:** Complaint and Order issued February 14, 1995.<sup>1</sup>

**FOR FURTHER INFORMATION CONTACT:** Claudia Higgins or Ann Malester, FTC/S-2224, Washington, DC 20580. (202) 326-2682.

**SUPPLEMENTARY INFORMATION:** On Monday, November 28, 1994, there was published in the **Federal Register**, 59 FR 60807, a proposed consent agreement with analysis in the Matter of American Home Products Corporation, for the purpose of soliciting public comment. Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to divest, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interpret or apply sec. 5, 38 Stat. 719, as amended; sec. 7, 38 Stat. 731, as amended; 15 U.S.C. 45, 18)

**Donald S. Clark,**  
Secretary.

[FR Doc. 95-5787 Filed 3-8-95; 8:45 am]

BILLING CODE 6750-01-M

[File No. 951 0002]

**Boston Scientific Corporation;  
Proposed Consent Agreement With  
Analysis To Aid Public Comment**

**AGENCY:** Federal Trade Commission.

**ACTION:** Proposed consent agreement.

**SUMMARY:** In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would permit, among other things, Boston Scientific Corporation, a Massachusetts-based manufacturer and marketer of catheters, to proceed with the proposed acquisitions of Cardiovascular Imaging Systems, Inc., and SCIMED Life Systems, Inc., but would require the respondent to grant a non-exclusive license to a specified package of patents and technology related to the manufacture, production and sale of intravascular ultrasound (IVUS) imaging catheters to the Hewlett-Packard Company or another Commission-approved licensee. When the consent

becomes final, the license would have to be granted within ten days to Hewlett-Packard or within six months to another licensee. In addition, the consent agreement would require the respondent to obtain Commission approval, for ten years, before acquiring an interest greater than one percent in a company engaged in researching, developing or manufacturing IVUS catheters for sale in the United States.

**DATES:** Comments must be received on or before April 10, 1995.

**ADDRESSES:** Comments should be directed to: FTC/Office of the Secretary, Room 159, 6th St. and Pa. Ave., N.W., Washington, D.C. 20580.

**FOR FURTHER INFORMATION CONTACT:** Howard Morse or Robert Tovsky, FTS/S-3627, Washington, D.C. 20580. (202) 326-2949 or 326-2634.

**SUPPLEMENTARY INFORMATION:** Pursuant to Section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and § 2.34 of the Commission's Rules of Practice (16 CFR 2.34), notice is hereby given that the following consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. Public comment is invited. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with § 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii)).

**Agreement Containing Consent Order**

The Federal Trade Commission ("Commission"), having initiated an investigation of the proposed acquisitions by Boston Scientific Corporation of Cardiovascular Imaging Systems, Inc. and SCIMED Life Systems, Inc., and it now appearing that Boston Scientific Corporation, hereinafter sometimes referred to as "proposed respondent," is willing to enter into an agreement containing an order to license or divest certain assets, and to cease and desist from making certain acquisitions, and providing for other relief:

It Is Hereby Agreed by and between proposed respondent, by its duly authorized officers and attorney, and counsel for the Commission that:

1. Proposed respondent Boston Scientific Corporation is a corporation organized, existing and doing business under and by virtue of the laws of the State of Delaware with its office and principal place of business located at 1 Boston Scientific Place, Natick, Massachusetts, 01760-1537.

2. Proposed respondent admits all the jurisdictional facts set forth in the draft of complaint.

3. Proposed respondent waives:

- a. Any further procedural steps;
- b. The requirement that the Commission's decision contain a statement of findings of fact and conclusions of law;
- c. All rights to seek judicial review or otherwise to challenge or contest the validity of the order entered pursuant to this agreement; and
- d. Any claim under the Equal Access to Justice Act.

4. This agreement shall not become part of the public record of the proceeding unless and until it is accepted by the Commission. If this agreement is accepted by the Commission it, together with the draft of complaint contemplated thereby, will be placed on the public record for a period of thirty (30) days and information in respect thereto publicly released. The Commission thereafter may either withdraw its acceptance of this agreement and so notify the proposed respondent, in which event it will take such action as it may consider appropriate, or issue and serve its complaint (in such form as the circumstances may require) and decision, in disposition of the proceeding.

5. This agreement is for settlement purposes only and does not constitute an admission by proposed respondent that the law has been violated as alleged in the draft of complaint, or that the facts as alleged in the draft complaint, other than jurisdictional facts, are true.

6. This agreement contemplates that, if it is accepted by the Commission, and if such acceptance is not subsequently withdrawn by the Commission pursuant to the provisions of § 2.34 of the Commission's Rules, the Commission may, without further notice to the proposed respondent, (1) issue its complaint corresponding in form and substance with the draft of complaint and its decision containing the following order to license, divest and cease and desist in disposition of the proceeding and (2) make information public with respect thereto. When so entered, the order to license, divest and cease and desist shall have the same force and effect and may be altered, modified or set aside in the same manner and within the same time provided by statute for other orders. The order shall become final upon service. Delivery by the United States Postal Service of the complaint and decision containing the agreed-to order to proposed respondent's address as stated in this agreement shall constitute

<sup>1</sup> Copies of the Complaint, the Decision and Order, and Commissioner Azcuenaga's statement are available from the Commission's Public Reference Branch, H-130, 6th Street & Pennsylvania Avenue, NW., Washington, DC 20580.